Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|October 1, 2025
7 Pulmonology Headlines You Missed in September 2025
Author(s)Victoria Johnson
Fact checked by: Tim Smith
September 2025 saw 1 new approval, new long term data on smoking and emphysema, and more.
Advertisement
Advertisement
September 2025 brought a mix of advances and setbacks in pulmonology, with new clinical trial readouts and regulatory updates highlighting the evolving landscape of respiratory care. Landmark data in idiopathic pulmonary fibrosis, sarcoidosis, and emphysema underscored both the promise of novel therapies and the ongoing challenges of treating progressive lung disease. At the same time, large-scale studies shed light on the intergenerational effects of smoke exposure, reinforcing the long-term importance of preventive measures in public health.
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Advertisement
Advertisement